Embolism Diagnostic Market: 2017 Global Industry Trends 2021 Embolism Diagnostic Industry Global Market | Page 3

Pulmonary Embolism Diagnostic Market - Global Industry Analysis, Size,
Share, Growth, Trends and Forecasts 2017 – 2021
Scope of the Report:
“Pulmonary Embolism Diagnostic Market: Size, Trends & Forecasts (2017-2021)”, provides an in-depth
analysis of the developed region pulmonary embolism diagnostic market by value, by volume (number of
patients), by segments, etc.
The report provides an analysis of the developed regions such as Canada, Australia and Europe on the basis
of diagnostics penetration and the regions such as the US with an addressable market opportunity for the
diagnostics penetration.
The report also assesses the key opportunities in the market and outlines the factors that are and will be
driving the growth of the industry. Growth of the pulmonary embolism diagnostics market has also been
forecasted for the period 2017-2021, taking into consideration the previous growth patterns, the growth
drivers and the current and future trends.
The competition in the Pulmonary Embolism Diagnostic Market, especially V/Q scan is dominated by one
big player at global level, Cyclopharm and at regional level, in the US, the competition is dominated by
Lantheus Holdings, Inc. (Xe-133).
Further, key players of the global pulmonary thromboembolism diagnostic market Cyclopharm, Philips,
Siemens and Jubilant LifeSciences Limited are also profiled with their financial information and respective
business strategies.
Purchase a Copy of This Report at
http://www.marketreportsonline.com/contacts/purchase.php?name=585820